Prolactin and Autoimmunity

Vânia Vieira Borba1,2,3, Gisele Zandman-Goddard3 and Yehuda Shoenfeld3,4*

1Department “A” of Internal Medicine, Coimbra University Hospital Centre, Coimbra, Portugal, 2Faculty of Medicine, University of Coimbra, Coimbra, Portugal, 3Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, 4Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

The great asymmetry of autoimmune diseases between genders represents one of the most enigmatic observations among the mosaic of autoimmunity. Sex hormones are believed to play a crucial role in this dimorphism. The higher prevalence of autoimmunity among women at childbearing ages, disease onset/relapses during pregnancy, and post-partum are some of the arguments that support this hypothesis. Certainly, motherhood represents one of the most remarkable challenges for the immune system, which not only has to allow for the conceptus, but also has to deal with complex endocrine alterations. Hormonal homeostasis is known to exert a crucial influence in achieving a competent and healthy immune system. Prolactin (PRL) has a bioactive function acting as a hormone and a cytokine. It interferes with immune system modulation, mainly inhibiting the negative selection of autoreactive B lymphocytes. Likewise, hyperprolactinemia has been described in relation to the pathogenesis and activity of several autoimmune disorders. Dopamine is an effective inhibitor of PRL secretion due to either a direct influence on the hypophysis or stimulation of postsynaptic dopamine receptors in the hypothalamus, arousing the release of the PRL inhibitory factor. Hence, dopamine agonists have proven to offer clinical benefits among autoimmune patients and represent a promising therapy to be explored. In this review, we attempt to provide a critical overview of the link between PRL, autoimmune diseases, and motherhood.

Keywords: sex hormones, prolactin, autoimmunity, systemic lupus erythematosus, multiple sclerosis, systemic sclerosis

INTRODUCTION

Currently, more than 80 autoimmune disorders are recognized, in which aberrant immune responses against self-different organs and tissues play a crucial role (1). Gender dimorphism represents one of the most enigmatic observations among the mosaic of autoimmunity. Susceptibility genes, epigenetic modifications, gender-related composition of gut microbiota, and sex hormones are believed to be a mainstay of this asymmetry (2, 3). The greater prevalence of autoimmunity among childbearing age women, disease relapses during pregnancy, and post-partum are some of the arguments that support this hypothesis (4). Indeed, women have enhanced immune reactivity, larger antigen-presenting capability and mitogenic responses, increased antibody production, higher immunoglobulin (Ig) levels, and the ability to reject allografts more rapidly (5). The immune and neuroendocrine system

Abbreviations: IFN, interferon; Ig, immunoglobulin; IL, interleukin; MAPK, mitogen-activated protein kinase; MHC, major histocompatibility complex; PRL, prolactin; PRLR, prolactin receptor; Th, T helper cells; TNF, Tumor necrosis factor; Treg, T regulatory cells; STAT1, Signal transducer and activator of transcription 1.
are intimately connected, partaking of dynamic bidirectional communication. Prolactin (PRL) has a recognized immuno-stimulatory effect, specially inhibiting the negative selection of autoreactive B lymphocytes, promoting autoimmunity. In accordance, hyperprolactinemia has been associated with several autoimmune diseases, influencing its pathogenesis (6). Although the mechanisms involving this interaction are not completely understood, it has been documented that PRL can influence the communication and regulation of immune cells (7).

PRL, THE HORMONE, AND THE CYTOKINE

Prolactin is a 23-kD peptide hormone secreted in the pituitary gland, through the hypothalamic–pituitary–adrenal axis, under tonic inhibition of dopamine. Interestingly, this hormone can also be produced in extra-pituitary locations, such as decidua, ovary, prostate, mammary gland, adipose tissue, brain, and immune cells. When produced in extra-pituitary sites, PRL has different molecular weight and bioactivity. Hyperprolactinemia is usually defined as fasting levels of above 20 ng/ml in men and above 25 ng/ml in women (8). The expected rate among healthy population is up to 3%. Levels physiologically increase during lactation, but also as result of several diseases, including prolactinoma, hypothyroidism, and adrenal insufficiency (9). Besides, PRL secretion is regulated by cytokines such as interleukin (IL)-1, IL-2, and IL-6, which are stimulators, while endothelin-3 and interferon (IFN)-γ play an inhibitory role. This hormone can be found adopting several isoforms due to variations in post-translational modifications (10). The three main isoforms are the monomeric (free little PRL), big PRL, and macroprolactin (big big). The most biologically potent isoform is the monomeric free (little) PRL, which consists of 199 amino acids and has a molecular weight of 23 kDa (11). The PRL receptor is a member of the type 1 cytokine/hematopoietic receptor superfamily and is widely expressed through the immune system, including monocytes, lymphocytes, macrophages, natural killer cells, granulocytes, and thymic epithelial cells (12). Hence, the binding of PRL to its receptor activates downstream signaling pathways that will manipulate immune cells proliferation, differentiation, secretion, and survival (13, 14). This molecule is an integral member of the immune-neuroendocrinology network and has been largely associated with autoimmune diseases (15).

PRL and Immune Modulation

Prolactin strongly persuades the innate and adaptive immune responses, managing the maturation of CD4− CD8− thymocytes to CD4+ CD8+ T cells, through IL-2 receptor expression (16, 17). A direct correlation between PRL levels and the number of B and CD4+ T lymphocytes has been reported (18). Indeed, hyperprolactinemia can impair B-cell clonal deletion, deregulate receptor editing and diminish the threshold for activation of B cells, promoting auto-reactivity (19–21). It is capable of changing Th1 and Th2 type cytokine production, promoting IL-6 and INF-γ secretion, and playing a regulatory role on IL-2 levels (22, 23). Furthermore, PRL increases Ig production, stimulates the development of antigen-presenting cells expressing major histocompatibility complex class II, and upholds the co-stimulatory molecules CD86, CD80, and CD40 (24). Interestingly, assorted autoantibodies, including anti-cardiolipin, anti-PRL, anti-La, anti-Ro, among others, were detected in patients with hyperprolactinemia (25–27). Finally, PRL has been shown to influence dendritic cells to skew antigen presentation to pro-inflammatory function phenotype, enhancing IFN-α production (28). During pregnancy, one of the most decisive immunologic adaptations is the shift from a Th1/Th17 pro-inflammatory response toward a Th2/T regulatory cell (Treg) response, which promotes tolerance and inhibits natural killer cells cytotoxicity (2, 29). In accordance, differences in the activity of assorted autoimmune diseases have been reported during pregnancy and post-partum. For a better comprehension, the effects of PRL on the immune system cells were summarized in Table 1.

PRL during Pregnancy and Breastfeeding

Sex hormones can influence different functions on the immune system network. Typically, PRL and estrogens act as immune stimulants, while progesterone and testosterone exert a suppressive role (51, 52). Pregnancy inspires unique changes in endocrine and immune signaling, in order to tolerate and support the development and survival of the placenta and fetus in the hostile maternal immune system environment. PRL levels increase during pregnancy and reach peak values during delivery (53). Suckling stimulates the nerve endings in the nipple-areolar complex and strongly promotes hormone production. A large study performed by Stuebe et al. (54) evaluated PRL levels in women who exclusively breastfed their infants. The authors successfully reported wide changing baseline values (from 9 ng/dl before to 74 ng/dl 10 min after breastfeeding), depending on the frequency of feedings (54). In accordance, during the pregnancy and lactation period, several patients experience disease onset or relapse, suggesting an active influence of PRL. Indeed, a significant association between PRL levels and disease activity was found in systemic lupus erythematosus (55), rheumatoid arthritis (50, 56), and peripartum cardiomyopathy patients (57, 58), therefore breastfeeding should not be encouraged among those patients.

PRL and the Role of Dopamine Agonists

Dopamine is an effective inhibitor of PRL secretion due either a direct influence on the hypophysis or stimulation of postsynaptic dopamine receptors in the hypothalamus, arousing the release of the PRL inhibitory factor. Bromocriptine is an ergot alkaloid that binds to the dopamine receptor and inhibits the central synthesis of PRL. In addition, this drug can also influence T and B lymphocytes through the dopamine receptor (59, 60). Bromocriptine has been shown to decrease autoantibodies production, influence lymphocyte function and modulate the expression of surface molecules. By contrast, it exerts no clear effect on extra-pituitary PRL production. In conclusion, the beneficial therapeutic effects in murine and human trials, and the low toxicity of the drug outline a solid rationale for its attempt in future therapeutic proposals (61).
TABLE 1 | Effects of prolactin (PRL) on the immune system cells.

| Immune cells | PRL secretion | Prolactin receptor (PRLR) expression | Immunological effects of PRL | Reference |
|--------------|--------------|--------------------------------------|----------------------------|----------|
| Thymocytes   | ✓            | ✓                                    | Promote the differentiation of CD4−/CD8− thymocytes into CD4+CD8+ cells | (30, 31) |
|              |              |                                      | Regulate the maintenance of thymocyte viability during differentiation |         |
|              |              |                                      | Enhance the production of cytokines (IL-12, TNF-α, IL-1β) | (32, 33) |
|              |              |                                      | Increase the responsiveness in allogeneic mixed leukocyte reactions (upregulation of MHC surface expression and the co-stimulatory molecule CD80) |         |
| Dendritic cells | ?          | ✓                                    | Exert an immunomodulatory role at early stages of T-cell activation | (34–37) |
|              |              |                                      | Increase secretion of TNF-α, IFN-γ, and IL-2 |         |
|              |              |                                      | Trigger the IL-2-stimulated proliferation |         |
|              |              |                                      | Promote dysfunction of regulatory T cells |         |
| T cells      | ✓            | ✓                                    | Influence adhesion to endothelial cells | (38, 39) |
| B cells      | ✓            | ✓                                    | Increase B-cell maturation process, promoting the survival of self-reactive clones | (40–42) |
| Natural killer cells | ?      | ✓                                    | Increase the viability of immature B cells by rescuing them from apoptosis |         |
|              |              |                                      | Induce natural killer cells differentiation to PRL-activated killer cells (PAK cells) in a dose-dependent way |         |
|              |              |                                      | Interfere with proliferation and cytotoxic activity |         |
| Monocytes    | ✓            | ✓                                    | Promote the release of IFN-γ | (43–45) |
| Granulocytes | ?            | ✓                                    | Increase TNF expression |         |
| Macrophages  | ✓            | ✓                                    | Activate the STAT1 and MAPK pathways | (46, 47) |
|              |              |                                      | Contribute for the transcription of IRF-1 and iNOS |         |
|              |              |                                      | Cooperate with other pro-inflammatory stimuli to activate macrophages via engagement with the PRLR | (7, 48–50) |
|              |              |                                      | Promote the secretion of chemokines and cytokines (IL-1β, IL-12β, IFN-γ, and TNF) |         |

INOS: inducible nitric oxide synthase; IFN, interferon; IL, interleukin; IRF-1, interferon regulatory factor 1; MAPK, mitogen-activated protein kinase; MHC, major histocompatibility complex; STAT1, signal transducer and activator of transcription 1; TNF, tumor necrosis factor.

HYPERPROLACTINEMIA AND AUTOIMMUNE DISEASES

Hyperprolactinemia has been reported in patients with several autoimmune diseases, commonly manipulating disease development and perpetuation (62). The link between PRL and autoimmunity has been proposed to have a genetic background (63, 64). The PRL gene is located on the short arm of chromosome 6, near the HLA-DRB1 region, which is known for its association with assorted immune-mediated disorders (65).

PRL and Systemic Lupus Erythematosus

Systemic lupus erythematosus is an autoimmune disease, typically affecting young women at reproductive age (66). Hyperprolactinemia has been reported in a wide range of lupus patients from both genders (15–33%). In accordance, PRL levels have shown direct correlation with clinical and serological disease activity (16, 67–69). Results from several trials report also an association with neurological, renal and hematological involvement, serositis, enhanced anti-double-stranded DNA antibodies, and diminished complement (70, 71). Furthermore, PRL bolsters the development of lupus-like phenotype in non-prone mice and exacerbated the disease in a lupus murine experimental study (72). During pregnancy, hyperprolactinemia has been associated with lupus anticoagulant, disease activity, and poor outcomes for mother and fetus (73). In accordance, the presence of anti-PRL antibodies was correlated with lower disease activity and better outcomes in pregnant patients (74, 75). The treatment of pregnant women with bromocriptine was shown to prevent disease relapses, improve outcomes, and reduce the doses of concomitant steroidal therapy (76, 77). In conclusion, the evidence strongly supports the role of PRL in the pathogenesis and activity of systemic lupus erythematosus.

PRL and Anti-Phospholipid Syndrome

Anti-phospholipid syndrome is a systemic autoimmune condition, characterized by thrombotic events and/or pregnancy morbidity in the presence of anti-phospholipid antibodies. Hyperprolactinemia was detected in 12% of patients with anti-phospholipid syndrome, with no differences among genders or disease subtypes. Likewise, hormone levels were shown to be correlated with the presence of lupus anticoagulants, intrauterine growth retardation, and miscarriages among pregnant patients (78). By contrast, no significant correlation was found with thrombotic events, although PRL was recently proposed as a novel risk factor for thrombotic disease, since it acts as a potent platelet aggregation co-activator (79–82). Previously, bromocriptine was tested in animal models with anti-phospholipid syndrome and lupus, showing a suppressive effect on both diseases, probably through induction of natural non-specific CD8 suppressor cells (59).

PRL and Rheumatoid Arthritis

Rheumatoid arthritis is a chronic autoimmune disease that if untreated leads to progressive and irreversible destruction of cartilage and bone. The relationship between PRL and rheumatoid arthritis emerged from the adjacent location of the human PRL gene and HLA region (16). Recent studies reported higher levels of PRL in serum and synovial fluid of patients with rheumatoid arthritis. This suggests increased production, either systemic or locally secreted by immune cells, in putative relation with disease activity (45, 56). Pregnant women with
rheumatoid arthritis, due to a transient period of hypercortisolism, experience disease improvement. After delivery, flares are frequently reported (83). Women who breastfeed after the first pregnancy have a higher risk of developing rheumatoid arthritis, suggesting an active influence from PRL (84, 85). In addition, nearly 90% of these women will relapse within the first 3 months of postpartum and almost all patients will flair within the next 9 months. Indeed, severe disease was associated with longer breastfeeding periods and higher number of breast fed children. In animal models, bromocriptine was able to suppress postpartum exacerbation of collagen-induced arthritis (86). In humans, the treatment with bromocriptine revealed controversial findings (87, 88), probably because bromocriptine does not influence lymphocyte-derived PRL production (89). Hence, systemic and locally produced PRL may offer distinct contributions to inflammatory arthritis.

PRL and Systemic Sclerosis
Systemic sclerosis is a connective tissue disease characterized by alterations of the microvasculature, disturbances of the immune system, and massive deposition of collagen and other matrix substances in the skin and internal organs (90). High levels of PRL have been reported in 13–59% of patients with systemic sclerosis (91). Likewise, a significant correlation between hormone levels and the severity of skin sclerosis, lung, and cardiovascular involvement was found (92–94). The sources of PRL in this disease are believed to reside on enhanced lymphocytic secretion, increased dopaminergic central tone, and drug-induction, mainly by antidepressants and prokinetics (95). Pregnancy per se does not exacerbate the disease, even though cases have been reported of women with organ insufficiency mainly pulmonary hypertension and severe skin fibrosis (96, 97). Patients with disease duration of less than 4 years, with diffuse cutaneous subtype, presence of anti-RNA polymerase III or anti-topoisomerase I antibodies are at higher risk for obstetric complications and should delay pregnancy until the disease is quiescent (98). In conclusion, PRL was found to be correlated with disease severity and activity.

PRL and Multiple Sclerosis
Multiple sclerosis is a chronic inflammatory disorder involving the central nervous system (99, 100). In animal models, it is represented by experimental autoimmune encephalomyelitis, believed to be an inflammatory response against oligodendrocytes that form myelin sheaths surrounding neuronal axon driven by myelin-reactive CD4+ Th1/Th17 cells (101). Several studies reported a positive correlation between hyperprolactinemia and disease onset, relapse, and number of anti-myelin oligodendrocyte glycoprotein antibody secreting cells (102, 103). Indeed, the source of high PRL levels among those patients is unclear, albeit observations suggest that it may be part of a non-specific hypothalamic–pituitary–adrenal axis dysregulation due to neurodegeneration and/or demyelination (104). Currently, PRL is believed to have a dual impact in the central nervous system. On the one hand, PRL might support system repair by providing regenerative signals for neurons, oligodendrocytes, and adult neural stem/progenitor cells. On the other hand, its stimulation of peripheral immune cells might promote aberrant immune responses and negatively impact the disease (105, 106). Typically, pregnancies were believed to have a negative impact in women with multiple sclerosis, provoking postpartum exacerbations and increasing permanent disability (107). Nowadays, it is known that the risk of relapse significantly declines during the third trimester of pregnancy and increases three-fold in the first 3–4 months after delivery, with no references about medication consumption or breastfeeding options (108). Recently, studies revealed that an earlier return of menses was associated with a higher risk of disease relapse in the first 6 months after delivery, which suggests a natural protection from exclusive breastfeeding (109). Likewise, prolonged lactational amenorrhea was correlated with a lower risk of postpartum relapses (110). In conclusion, evidence supports a plausible protection from exclusive breastfeeding, although no studies have examined the long-term effects of breastfeeding, particularly in exclusive patterns.

PRL and Celiac Disease
Celiac disease is a gluten-sensitive autoimmune enteropathy where both adaptive immunity and innate immunity are involved in its development (111). Serum PRL levels were positively correlated with disease activity, degree of mucosal atrophy, and with the serum concentration of anti-endomysial antibodies. Recently, a longitudinal study revealed diminished levels of PRL after 6 months following a gluten-free diet. The evidence of decreasing PRL simultaneously with the decline of anti-transglutaminase antibodies suggests a direct connection with a gluten-free diet and hormone levels (112).

PRL and Autoimmune Thyroid Disease
Autoimmune thyroid diseases comprise mainly two disorders, Grave’s disease and Hashimoto thyroiditis (113). Hyperprolactinemia was found in 20% of patients with autoimmune thyroid disease and had double the frequency among hypothyroidism patients. Around 90% of Hashimoto’s thyroiditis patients presented significantly higher PRL levels in association with decreased cortisol titers (114). The role of dopamine agonists in the treatment of autoimmune thyroid disease is yet to be determined.

PRL and Peripartum Cardiomyopathy
Peripartum cardiomyopathy is a congestive heart failure occurring in the last month of pregnancy or 5 months after delivery, in the absence of preexisting heart disease (115). The etiology of this disease remains unclear, although plausible causes have been proposed, such as nutritional deficiency, viral infections, stress-activated cytokines, pathological response to hemodynamic stress, inflammation, and autoimmune reactions (116). Evidence supports an active role of PRL in the pathophysiology of this disease. Increased oxidative stress leads to subsequent 16-kDa PRL production, impairing the cardiac vasculature and its metabolism, culminating in systolic heart failure (117, 118). Interestingly, the presence of autoantibodies against sarcomeric myosin and troponin I were detected among women with peripartum myocardopathy, suggesting the presence of an underlying autoimmune disorder. In addition, these antibodies were associated with the severity of left ventricle dysfunction and
lower rate of full cardiac recovery on follow-up (119). Interestingly, patients demonstrated an abnormal cytokine profile (increased levels of TNF, IL-6 and soluble Fas receptors), decreased levels of CD4+ CD25lo Tregs, a heightened level of fetal microchimerism, and a significant reduction in the plasma levels of progesterone, estradiol, and relaxin, contributing to abnormal immune responses and inflammatory processes (120, 121). Recently, dopamine agonists have shown promising results in the treatment of this disease, dramatically improving outcomes (58, 122–124). The 2010 European position statement does not encourage breastfeeding based on concerns regarding the perpetuation of PRL pathways (125).

CONCLUSION

The dimorphism between genders in autoimmune diseases is believed to rely on sex hormones. PRL exerts a great influence in immune system modulation, mainly inhibiting the negative selection of autoreactive B lymphocytes and has been associated with the pathogenesis of several autoimmune disorders. During pregnancy and the lactation period, assorted autoimmune patients experience disease relapse, suggesting an active influence of PRL. Immunological studies of pregnant and postpartum women with autoimmune diseases offer a biologically rich opportunity to improve our understanding of the hormonal impact on disease relapse pathophysiology. Although the interest on the relationship between PRL, immune modulation, and autoimmune diseases has emerged in the past few years, more studies are required to further delineate the influence of PRL in autoimmune disease. Eventually, gut microbiome, immune cells transcriptome, and proteome might be the answers to those questions being unsolved to date.

Highlights

- Susceptibility genes, epigenetic modifications, microbiome, and sex hormones are believed to be a mainstay of the gender asymmetry in autoimmune diseases.
- PRL influences the negative selection of autoreactive B cells, promoting their proliferation, survival, and antibody production.
- Hyperprolactinemia has been associated with several autoimmune diseases and is believed to play a crucial role in their pathogenesis.
- A significant association between PRL and disease flairs was found in systemic lupus erythematosus and rheumatoid arthritis.
- Dopamine agonists have been used in the treatment of many autoimmune diseases with great benefits.

AUTHOR CONTRIBUTIONS

VB, ZG, and YS contributed equally to the construction of this review.

REFERENCES

1. Perricone R, Perricone C, Shoenfeld Y. Autoimmunity: when the immune system becomes the self-ish giant. Autoimmun Rev (2011) 10(10):575–6. doi:10.1016/j.autrev.2011.05.003
2. Ortona E, Pierdominici M, Maselli A, Veroni C, Aloisi F, Shoenfeld Y. Sex-based differences in autoimmune diseases. Ann Ist Super Sanita (2016) 52(2):205–12. doi:10.4415/ann_16_02_12
3. Krasselt M, Baerwald C. Sex, symptom severity, and quality of life in rheumatology. Clin Rev Allergy Immunol (2017) 11:1–16. doi:10.1007/s12016-017-8631-6
4. Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev (2007) 6(8):537–42. doi:10.1016/j.autrev.2006.10.005
5. Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev (2007) 6(6):366–72. doi:10.1016/j.autrev.2006.10.001
6. Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Ann Reprod Immunol (1991) 26(3):118–23. doi:10.111/j.1600-0897.1991.tb00708.x
7. Tang MW, Garcia S, Gerlag DM, Tak PP, Reedquist KA. Insight into the endocrine system and the immune system: a review of the inflammatory role of prolactin in rheumatoid arthritis and psoriatic arthritis. Front Immunol (2017) 8:720. doi:10.3389/fimmu.2017.00720
8. Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci (2013) 6(3):168–75. doi:10.4103/0974-1208.121400
9. Savino W. Prolactin: an immunomodulator in health and disease. Front Horm Res (2017) 48:69–75. doi:10.1007/978-3-319-045290
10. Thoreau E, Petridou B, Kelly PA, Djiane J, Monron JP. Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis. FEBS Lett (1991) 282(1):26–31. doi:10.1016/0014-5793(91)80437-8
11. Marcotegui AR, Garcia-Calvo A. [Biochemical diagnosis of monomeric hyperprolactinemia]. An Sist Sanit Navar (2011) 34(2):145–52. doi:10.4321/S1137-66272011000200002
12. Orbach H, Zandman-Goddard G, Amital H, Barak V, Szeke次要 Z, Szucs G, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann NY Acad Sci (2007) 1109:385–400. doi:10.1196/annals.1398.044
13. Thoreau E, Petridou B, Kelly PA, Djiane J, Monron JP. Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis. FEBS Lett (1991) 282(1):26–31. doi:10.1016/0014-5793(91)80437-8
14. Jeganathan V, Peeva E, Diamond B. Hormonal milieu at time of B cell activation controls duration of autoantibody response. J Autoimmun (2014) 53:46–54. doi:10.1016/j.jaut.2014.02.007
15. Anaya JM, Shoenfeld Y. Multiple autoimmune disease in a patient with hyperprolactinemia. Isr Med Assoc J (2005) 7(11):740–1.
16. Vera-Lastra O, Lara JL, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev (2002) 1(6):360–4. doi:10.1016/S1568-9972(02)00081-2
17. Pereira Suarez AL, Lopez-Rincon G, Martinez Neri PA, Estrada-Chavez C. Prolactin in inflammatory response. Adv Exp Med Biol (2015) 846:243–64. doi:10.1007/978-3-319-12114-7_11
18. Brand JM, Frohn C, Czaiukka P, Brockmann C, Kirchner H, Luhm J. Prolactin triggers pro-inflammatory immune responses in peripheral immune cells. Eur Cytokine Netw (2004) 15(2):99–104.
19. Buckley AR. Prolactin, a lymphocyte growth and survival factor. Lupus (2001) 10(10):684–90. doi:10.1191/096120301717164912
20. Kochendoerfer SK, Krishnan N, Buckley DJ, Buckley AR. Prolactin regulation of Bcl-2 family members: increased expression of bcl-xL but not mcl-1 or bad in Nbl-2-T cells. J Endocrinol (2003) 178(2):265–73. doi:10.1677/joe.0.1700265
21. Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E. Prolactin alters the mechanisms of B cell tolerance induction. Arthritis Rheum (2009) 60(6):1743–52. doi:10.1002/art.24500
22. Tomio A, Schust DJ, Kawana K, Yasugi T, Kawana Y, Mahalingaiah S, et al. Prolactin can modulate CD4+ T cell response through receptor-mediated alterations in the expression of T-bet. Immunol Cell Biol (2008) 86(7):616–21. doi:10.1038/icb.2008.29
23. Mackern-Oberti JP, Iara EL, Riedel CA, Kalgerris AM. Hormonal modulation of dendritic cells differentiation, maturation and function: implications for the initiation and progress of systemic autoimmunity. Arch Immunol Ther Exp (Warsz) (2017) 65(2):123–36. doi:10.1007/s00005-016-0418-6
44. Tang C, Li Y, Lin X, Ye J, Li W, He Z, et al. Prolactin increases tumor necrosis factor alpha expression in peripheral CD4+ monocytes of patients with rheumatoid arthritis. *Cell Immunol* (2014) 290(1):164–8. doi:10.1016/j.cellimm.2014.06.005

45. Tang MW, Reeedquist KA, Garcia S, Gerdl GM, Tak PP. 1.57 Prolactin is locally produced in the synovium of patients with inflammatory arthritis and promotes macrophage activation. *Ann Rheum Dis* (2014) 73(Suppl 1):A24. doi:10.1136/annrheumdis-2013-205124.56

46. Materia L, Galetto A, Geuna M, Vekemans K, Ricotti E, Contarini M, et al. Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. *Immunology* (2000) 100(1):29–36. doi:10.1046/j.1365-2567.2000.00996.x

47. Dogusun Z, Hooge R, Verpoot P, Hooge-Peters EL. Cytokine-like effects of prolactin in human mononuclear and polymorphonuclear leukocytes. *J Neuroimmunol* (2001) 120(1):58–66. doi:10.1016/S0165-5728(01)00420-9

48. Tripathi A, Soda H. Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways. *Int Immunol* (2008) 20(3):327–36. doi:10.1093/intimm/dxm145

49. Carvalho-Freitas MI, Anselmo-Franci JA, Palermo-Neto J, Felcio LP. Prior reproductive experience alters prolactin-induced macrophage responses in pregnant rats. *J Reprod Immunol* (2013) 99(1–2):54–61. doi:10.1016/j.jri.2013.03.005

50. Parada-Turska J, Targonska-Stepniak B, Majdan M. *Prolactin in connective tissue diseases – a spotlight on the role of progestogens.* *J Reprod Immunol* (2016) 1107:129–35. doi:10.1016/j.jaut.2015.05.014

51. Boksa D, Berezin M, Gur H, Lin HC, Alosachie I, Terryberry JW, et al. Autoantibody profile in the sera of women with hyperprolactinemia. *J Autoimmun* (1995) 8(3):415–24. doi:10.1016/1006-4971(95)00033-1

52. Krause I, Blumenfeld Z, Malchinsky M, Cohen S, Blank M, Eldor A, et al. Anti-endothelial cell antibodies in the sera of hyperprolactinemic women. *Lupus* (1998) 7(6):377–82. doi:10.1097/00129845-199806000-00016

53. De Bellis A, Colao A, Pivenello R, Savoia A, Battaglia M, Ruocco G, et al. Antipituitary antibodies in idiopathic hyperprolactinemic patients. *Ann N Y Acad Sci* (2007) 1107:129–35. doi:10.1196/annals.1381.014

54. Matera L, Mori T, Galetto S, Geuna M, Vekemans K, Ricotti E, Contarini M, et al. Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. *Immunology* (2000) 100(1):29–36. doi:10.1046/j.1365-2567.2000.00996.x
to anti-cyclic citrullinated peptide-negative rheumatoid arthritis. *Arthritis Rheumatol* (2016) 68(7):1603–13. doi:10.1002/art.39619

66. Anaya JM, Shoenfeld Y, Cervera R. Systemic lupus erythematosus 2014. *Autoimmune Dis* (2014) 2014:274323. doi:10.1155/2014/274323

67. Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hipp E. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus (SLE) levels are related to the disease activity. *Lupus* (2001) 10(8):554–61. doi:10.1191/096120301765496888

68. Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, Di Carlo R. Elevated bioactive prolactin levels in systemic lupus erythematosus – association with disease activity. *J Rheumatol* (2001) 28(10):2216–21.

69. Cardenas-Mondragon G, Ulloa-Aguirre A, Isordia-Salas I, Goffin V, Leanos-Miranda A. Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. *J Rheumatol* (2007) 34(7):1514–21.

70. Leanos-Miranda A, Cardenas-Mondragon G. Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. *Rheumatology* (Oxford) (2006) 45(1):97–101. doi:10.1093/rheumatology/kei115

71. Obach H, Zandman-Goddard G, Boaz M, Agmon-Levin N, Amital H, Szekanecz Z, et al. Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients. *Clin Rev Allergy Immunol* (2007) 33(1):189–99. doi:10.1007/s12016-006-8256-0

72. Saha S, Tieng A, Pepeljugoski KP, Zandamg-Goddard G, Peeva E. Prolactin, other reproductive factors influence future risk of rheumatoid arthritis. *Arthritis Rheum* (2013) 65(1):1–11. doi:10.1002/art.37715

73. Jara LJ, Pacheco-Reyes H, Medina G, Angeles U, Cruz-Cruz P, Saavedra MA. Prolactin levels are associated with lupus activity, lupus anticoagulant, and poor outcome in pregnancy. *Ann N Y Acad Sci* (2007) 1118:218–26. doi:10.1196/annals.1422.024

74. Leanos A, Pascoe D, Fraga A, Blanco-Favela F. Anti-prolactin autoantibodies in systemic lupus erythematosus patients with associated hyperprolactinemia. *Lupus* (1998) 7(6):398–403. doi:10.1179/096120398678920280

75. Leanos-Miranda A, Cardenas-Mondragon G, Ulloa-Aguirre A, Isordia-Salas I, Parra A, Ramirez-Peredo J. Anti-prolactin autoantibodies in pregnant women with systemic lupus erythematosus: maternal and fetal outcome. *Lupus* (2007) 16(5):342–9. doi:10.1177/096120330707081917

76. Yang XY, Liang LQ, Xu HS, He M, Yao SZ, Zhan ZP, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. *Thromb Haemost* (2006) 96(1):38–44. doi:10.1111/j.1538-7881.2005.01303.x

77. Joffre S, Rodriguez-Reyna T, Macías-Reyes M, Yañez-Fuentes S, Pérez-Rosas A, et al. Bromocriptine vs. placebo in patients with active rheumatoid arthritis. *Ann Rheum Dis* (2001) 60(4):310–4. doi:10.1136/ard.60.4.310

78. Praprotnik S, Agmon-Levin N, Porat-Katz BS, Blank M, Meroni PL, Cervera R. Prolactin levels are associated with lupus activity, lupus anticoagulant, low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. *Br J Rheumatol* (1997) 36(4):426–32. doi:10.1093/rheumatology/36.4.426

79. Wallaschofski H, Kobsar A, Sokolova O, Eigenthaler M, Lohmann T. Enhanced serum prolactin in patients with systemic lupus erythematosus – association with disease activity. *J Rheumatol* (2017) 44(1):66–71. doi:10.3390/intjms17122026

80. Raaz D, Wallaschofski H, Stumpf C, Yilmaz A, Cicha I, Klinghammer L, et al. Enhanced prolactin levels are associated with lupus activity as disclosed by homologous receptor bioassays. *J Rheumatol* (2007) 34(7):1514–21.

81. Wallaschofski H, Lohmann T, Hild E, Kobsar A, Spilcke-Liss J, Vera-Lastra O, Jara LJ, Medina G, Rojas JL, Velazquez F, Ariza R, et al. Functional hyperprolactinemia and hypophyseal microadenoma in systemic sclerosis. *J Rheumatol* (2006) 33(6):1108–12.

82. Korda M, Leanos-Miranda A, Cardenas-Mondragon G, Ulloa-Aguirre A, Isordia-Salas I, Yañez-Fuentes S, Pérez-Rosas A, et al. Bromocriptine vs. placebo in patients with active rheumatoid arthritis. *Ann Rheum Dis* (2001) 60(4):310–4. doi:10.1136/ard.60.4.310

83. Wallaschofski H, Kobsar A, Sokolova O, Eigenthaler M, Lohmann T. Enhanced serum prolactin in patients with systemic lupus erythematosus – association with disease activity. *J Rheumatol* (2017) 44(1):66–71. doi:10.3390/intjms17122026

84. Wolf M, Mandl LA, Hankinson SE, Grodstein F. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses’ Health Study. *Arthritis Rheum* (2004) 50(11):3458–67. doi:10.1002/art.20021

85. Whyte A, Williams RO. Bromocriptine suppresses postpartum exacerbation of collagen-induced arthritis. *Arthritis Rheum* (1988) 31(7):927–8. doi:10.1002/arp.1703101717

86. Figueroa F, Carrion F, Martinez ME, Rivero S, Mamani I, Gonzalez G. [Effects of bromocriptine in patients with active rheumatoid arthritis]. *Rev Med Chil* (1998) 126(1):33–41.

87. Salesi M, Sadeghizadavazhare S, Nasri P, Namdarigharagahi N, Farajzadegan Z, Hajalikhani M. The role of bromocriptine in the treatment of patients with active rheumatoid arthritis. *Int J Rheum Dis* (2013) 16(6):662–6. doi:10.1111/1756-185x.12015

88. Zornitsky S, Yong VW, Weiss S, Metz LM. Prolactin in multiple sclerosis. *Multi Scler* (2013) 19(1):15–23. doi:10.1177/1352458512458555

89. Costanza M, Binart N, Steinman L, Pedotti R. Prolactin: a versatile regulator of inflammation and autoimmune pathology. *Autoimmun Rev* (2015) 14(3):223–30. doi:10.1016/j.autrev.2014.11.005

90. Costanza M, Pedotti R. Prolactin: friend or foe in central nervous system autoimmune inflammation? *Int J Mol Sci* (2016) 17(12):2026. doi:10.3390/ijms17122026
107. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Ther Adv Neurol Disord* (2012) 5(3):247–53. doi:10.1177/1753808012433192

108. Langer-Gould A, Huang S, Gupta R, Leimpeter AD, Greenwood E, Albers KR, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. *Arch Neurol* (2009) 66(8):958–63. doi:10.1001/archneur.2009.132

109. Hellwig K, Rockhoff M, Herbsttritt S, Borisow N, Haghikia A, Elias-Hamp B, et al. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. *JAMA Neurol* (2015) 72(10):1132–8. doi:10.1001/jamaneurol.2015.1806

110. Langer-Gould A, Gupta R, Huang S, Hagan A, Atkuri K, Leimpeter AD, et al. Interferon-gamma-producing T cells, pregnancy, and postpartum relapses of multiple sclerosis. *Arch Neurol* (2010) 67(1):51–7. doi:10.1001/archneurol.2009.304

111. Parra-Medina R, Molano-Gonzalez N, Rojas-Villarraga A, Agmon-Levin N, Arango MT, Shoenfeld Y, et al. Prevalence of celiac disease in latin america: a systematic review and meta-regression. *PLoS One* (2015) 10(5):e0124040. doi:10.1371/journal.pone.0124040

112. Delvecchio M, Faienza MF, Lonero A, Rutigliano V, Francavilla R, Cavallo L. Prolactin may be increased in newly diagnosed celiac children and adolescents and decreases after 6 months of gluten-free diet. *Horm Res Paediatr* (2014) 81(5):309–13. doi:10.1159/000357064

113. Dong YH, Fu DG. Autoimmune thyroid disease: mechanism, genetics and current knowledge. *Eur Rev Med Pharmacol Sci* (2014) 18(23):3611–8.

114. Yamamoto M, Iguchi G, Takeno R, Okimura Y, Sano T, Takahashi M, et al. Adult combined GH, prolactin, and TSH deficiency associated with circulatory support combined with high-dose bromocriptine therapy. *Eur Heart J* (2017) 38(35):2680–2. doi:10.1093/eurheartj/ehx428

115. Albers KB, et al. Exclusive breastfeeding and the risk of postpartum relapses of peripartum cardiomyopathy. *Eur J Heart Fail* (2014) 11(6):364–70. doi:10.1038/tnhcardio.2014.37

116. Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: a position statement from the European Society of Cardiology Working Group on peripartum cardiomyopathy. *Eur J Heart Fail* (2010) 12(8):767–78. doi:10.1093/eurjhf/hfq120

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Borba, Zandman-Goddard and Shoenfeld. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.